Wave Life Sciences' (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss [Yahoo! Finance]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
positive interim results from its Phase 1 INLIGHT trial evaluating WVE-007, which is an investigational RNA medicine for obesity. The data from the 240 mg single-dose cohort revealed that the drug improved body composition over 3 months. Unlike traditional GLP-1 therapies, which often cause muscle loss alongside fat reduction, WVE-007 achieved a 9.4% reduction in visceral fat and a 4.5% reduction in total body fat while simultaneously resulting in a 3.2% increase in lean mass (~4.0 lbs). WVE-007 operates by silencing the INHBE gene using a proprietary SpiNA siRNA design. This approach is rooted in human genetics; individuals with natural loss-of-function variants in the INHBE gene typically possess lower visceral fat and a reduced risk of type 2 diabetes and cardiovascular disease. By targeting Activin E, the protein product of INHBE, WVE-007 aims to treat the root causes of metabolic dysfunction. The safety profile of the drug appears favorable, with no serious or severe treatm
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing PortfolioGlobeNewswire
- WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=WVE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=WVE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
WVE
Earnings
- 11/10/25 - Miss
WVE
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 12/15/25 - Form SCHEDULE
- WVE's page on the SEC website